Xenetic Biosciences, Inc Appoints Maksim Mamonkin to Scientific Advisory Board
February 13, 2020 at 03:32 pm EST
Share
Xenetic Biosciences, Inc. announced has strengthened its Scientific Advisory Board with the appointment of Maksim Mamonkin, Ph.D., to aid in the development of the Company's XCART™ program for the treatment of B-cell lymphomas. Dr. Mamonkin directs a laboratory that focuses on investigating the mechanisms and effects of CAR signaling in therapeutic T cells and developing new engineered approaches using genome editing and synthetic biology to enhance cell therapy of aggressive hematologic malignancies. He oversees clinical translation of investigational therapies though cGMP manufacturing to the clinic and serves as a co-principal investigator on several ongoing and upcoming clinical trials of CAR T cells in hematologic malignancies at Baylor College of Medicine.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.